|
Norquetiapine HCl, 1.0 mg/mL
|
N-070
|
1.0 mg/mL (as free base) in Methanol
Norquetiapine is a primary active metabolite of quetiapine, marketed as the atypical antipsychotic Seroquel for the treatment of depression, bipolar disorder, and schizophrenia. It maintains most of the pharmacological effects of quetiapine with potencies similar to the parent drug.
|
|
|
|
Refer to R-023
|
R-015
|
500 ug/mL in Methanol
Rufinamide, marketed as Banzel® in the US and Inovelon® in the European Union, is a newer anticonvulsant and antiepileptic drug. The drug was approved by the US Food and Drug Administration (FDA) on November 14, 2008, for the treatment of partial seizures associated with Lennox-Gastaut syndrome in adults and children 4 years and older.
|
|
|